San Francisco, California, United States
I am biomedical scientist with an entrepreneurial engineering mindset—a proactive leader who thrives in dynamic environments. I excel in managing multiple priorities and deliver solutions for seemingly intractable problems, building high-performing teams through excellence, integrity, and accountability. ——— drug-hunter | biopharma | leadership | entrepreneurship | communication | innovation | vision | strategy | analytical thinking | adaptability | accountability | resilience
• Defined long-term company goals, vision, and strategy in formal business plan. • Planned global IP strategy, verified freedom-to-operate (FTO), prosecuted patents (USPTO, CNIPA, EPO), established company branding and protected trademark (DPMA). • Authored 4 patents and 5 peer-reviewed research articles detailing R&D outcomes. • Secured government funding from the NIA (SBIR grant) and initiated a collaboration with the NCI. • Invented target-focused cellular high-throughput screening assay for an underappreciated protease. • Identified allosteric modulators and clarified structure-activity relationship (SAR) in secondary assays. • Leveraged RNAseq and omics data to validate target biology and identify biomarker in silico. • Managed business development, negotiated contracts with collaborators, cultivated stakeholder engagement through monthly updates and customized presentations. • Oversaw financial (GAAP), corporate, and legal affairs in conjunction with external law firms maintaining detailed records, which allowed the company’s continued operation to this day.
Augmenting scientific peer review with AI
• Successfully advanced two immune-oncology programs from the discover to the development stage. • Managed internal and partnered programs consistently meeting development milestones and timelines. • Resolved mechanism of action (MOA) characterizing immune-oncology biologics in vitro and ex vivo. • Designed in vivo studies (PK/PD, safety, efficacy) aligning cross-functional teams and managing CROs. • Reviewed study reports and regulatory documents in support of go/no-go decisions and IND filings. • Demonstrated leadership by presenting the team’s progress to external partners, mentoring team members, and spearheading strategic initiatives to launch new development programs.
• Raised $120K seed funding (Y-Combinator) by engaging investor network.
• Guided future research directions investigating vascular basement membrane defects in the eye. • Established novel imaging methods to monitor ER-stress response pathways in vivo. • Recognized for expert project management for collaborations exploring intervention points for retinal degeneration and testing small molecules in multisystem disorders culminating in 8 publications.